Biodexa Pharmaceuticals Plc BDRX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Biodexa Pharmaceuticals Plc (BDRX) is a healthcare company listed in the US with a market value of about $1M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -118%.
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $2M in 2015 to $484443 in 2023, a decline of about 16.4% a year. It was profitable in 0 of the last 10 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $484443 | $840599 | $779081 | $468164 | $889957 | $2M | $1M | $2M |
| Net income | -$9M | -$7M | -$9M | -$9M | -$7M | -$30M | -$13M | -$19M | -$22M | -$25M |
| Free cash flow | -$8M | -$15M | -$9M | -$9M | -$9M | -$13M | -$9M | -$18M | -$18M | -$18M |
| EPS (diluted) | $-16.40 | $-13.69 | $-17.17 | $-17.56 | $-14.04 | $-57.77 | $-25.40 | $-36.70 | $-41.42 | $-47.35 |
| Net margin | — | — | -1858.0% | -1095.3% | -944.6% | -6469.1% | -1496.3% | -775.5% | -1624.3% | -1524.0% |
| ROIC | -74.2% | -97.4% | -147.4% | -212.8% | -55.8% | -312.2% | -34.9% | -54.4% | -29.1% | -14.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Biodexa Pharmaceuticals Plc pay a dividend?
Not currently.
Is Biodexa Pharmaceuticals Plc a good stock to buy?
We do not give buy or sell advice. Biodexa Pharmaceuticals Plc scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.